Grant: Emerging Team Grant: Rare Diseases - Basic/Clinical
University of British Columbia
$2,375,000.00
Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes
EF 2011-12
Résumé
Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and bad infections. Thus milder disease needs less toxic drugs. Different classifications and "scoring tools" are used to define the types and severity of vasculitis and to measure damage caused by disease or drugs. These in turn help direct how aggressively to treat a patient and to measure outcome. None of these tools have been assessed in children and the best balance of disease and treatment risks against outcome for children is not known. Although causes of these diseases in children and adults are probably the same, the effects of the disease and the responses (good and bad) to drugs will differ in growing children. Because specialists may see only one new child with any vasculitis each year, obtaining enough information to learn about childhood vasculitis will require massive cooperation. We will use an international web-based registry to which doctors from 50 or more centers can contribute patient data. We will determine the features which help better classify and diagnose children compared to adults. Through the web we will share with contributors, collective information on patients similarly classified and "scored" so that most successful treatments can be identified. Children with vasculitis are less likely to have diseases associated with aging, alcohol and smoking etc., and therefore may be a better group in whom to study the underlying biology of vasculitis. We will use this opportunity and collect spit, blood and tissue from registry patients for laboratory study with an aim to find tests to better classify, define and direct optimal treatment and outcomes.
Programme
Emerging Team Grant: Rare Diseases - Basic/Clinical
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
247548
Name
Cabral David Allan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Organization for Rare Disorders (Toronto, Ontario)
Instname2
Genetics
Theme2
Clinical
Prcname2
Emerging Team Grant: Rare Diseases
Projecttitle
Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$2,375,000
Cihrequipment2
$0
Programname2
Emerging Team Grant: Rare Diseases - Basic/Clinical
Keyworddelim
Biomarkers; Disease Classification; Genomics; Integrated Knowledge Translation; Outcomes; Pediatrics; Pharmacogenomics; Registry; Systems Biology; Vasculitis
Abstract
Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and bad infections. Thus milder disease needs less toxic drugs. Different classifications and "scoring tools" are used to define the types and severity of vasculitis and to measure damage caused by disease or drugs. These in turn help direct how aggressively to treat a patient and to measure outcome. None of these tools have been assessed in children and the best balance of disease and treatment risks against outcome for children is not known. Although causes of these diseases in children and adults are probably the same, the effects of the disease and the responses (good and bad) to drugs will differ in growing children. Because specialists may see only one new child with any vasculitis each year, obtaining enough information to learn about childhood vasculitis will require massive cooperation. We will use an international web-based registry to which doctors from 50 or more centers can contribute patient data. We will determine the features which help better classify and diagnose children compared to adults. Through the web we will share with contributors, collective information on patients similarly classified and "scored" so that most successful treatments can be identified. Children with vasculitis are less likely to have diseases associated with aging, alcohol and smoking etc., and therefore may be a better group in whom to study the underlying biology of vasculitis. We will use this opportunity and collect spit, blood and tissue from registry patients for laboratory study with an aim to find tests to better classify, define and direct optimal treatment and outcomes.
Competitiondate
201108
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Cabral, David Allan
Approvedterm
5 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $2,375,000~ $0~